Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

CME Available: https://auau.auanet.org/content/integrating-care-oncology-patients-establishing-multidisciplinary-oncology-clinic-advanced

This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.

Learning Objectives:

Describe the components of a multidisciplinary urologic cancer cancer and identify the best structure for the practice.

Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients

Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.

Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers.

Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.